Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product c... Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). Show more
Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.78 | -21.2359550562 | 17.8 | 18 | 13.22 | 529093 | 15.19612012 | CS |
4 | -2.4 | -14.6163215591 | 16.42 | 18.88 | 13.22 | 482552 | 16.6871973 | CS |
12 | -7.82 | -35.8058608059 | 21.84 | 22.83 | 13.22 | 486904 | 17.92434459 | CS |
26 | -8.55 | -37.8821444395 | 22.57 | 25.42 | 13.22 | 474090 | 19.73861142 | CS |
52 | -20.39 | -59.2560302238 | 34.41 | 41.545 | 13.22 | 597713 | 26.0627847 | CS |
156 | -40.98 | -74.5090909091 | 55 | 79.65 | 13.22 | 543542 | 39.94468978 | CS |
260 | 2.1 | 17.6174496644 | 11.92 | 79.749 | 6.44 | 455981 | 36.399228 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.